BCL2 and lymphoma: ABT-263, a novel oral Bcl-2 blocker that boosts anticancer effects in vitro by reducing the apoptosis threshold, has been shown to have cytotoxic activity against tumor cell lines that upregulates Bcl-2, such as small cell lung carcinoma and leukemia/lymphoma [59].